Combination of chemotherapy and immune checkpoint therapy by the immunoconjugates-based nanocomplexes synergistically improves therapeutic efficacy in SCLC

References

• Calles A, Aguado G, Sandoval C, Álvarez R. (2021). Immunotherapy in small cell lung cancer: one step at a time: a narrative review. Transl Lung Cancer Res 10:1571–87.
   PubMed Web of Science ®Google Scholar
• Chen CY, Chen WC, Hung CM, Wei YF. (2021). Chemotherapy or chemo-immunotherapy as first-line treatment for extensive-stage small-cell lung cancer: a meta-analysis. Immunotherapy 13:1165–77.
   PubMed Web of Science ®Google Scholar
• Chen L, Zhou L, Wang C, et al. (2019). Tumor-targeted drug and CpG delivery system for phototherapy and docetaxel-enhanced immunotherapy with polarization toward M1-type macrophages on triple negative breast cancers. Adv Mater 31:e1904997.
   PubMed Web of Science ®Google Scholar
• Danafar H, Sharafi A, Kheiri Manjili H, Andalib S. (2017). Sulforaphane delivery using mPEG-PCL co-polymer nanoparticles to breast cancer cells. Pharm Dev Technol 22:642–51.
   PubMed Web of Science ®Google Scholar
• Facchinetti F, Di Maio M, Tiseo M. (2020). Adding PD-1/PD-L1 inhibitors to chemotherapy for the first-line treatment of extensive stage small cell lung cancer (SCLC): a meta-analysis of randomized trials. Cancers 12:2645.
   PubMed Web of Science ®Google Scholar
• Farid S, Liu SV. (2020). Chemo-immunotherapy as first-line treatment for small-cell lung cancer. Ther Adv Med Oncol 12:1758835920980365.
   Web of Science ®Google Scholar
• Feng X, Jiang D, Kang T, et al. (2016). Tumor-homing and penetrating peptide-functionalized photosensitizer-conjugated PEG-PLA nanoparticles for chemo-photodynamic combination therapy of drug-resistant cancer. ACS Appl Mater Interfaces 8:17817–32.
   PubMed Web of Science ®Google Scholar
• Feng X, Yao J, Gao X, et al. (2015). Multi-targeting peptide-functionalized nanoparticles recognized vasculogenic mimicry, tumor neovasculature, and glioma cells for enhanced anti-glioma therapy. ACS Appl Mater Interfaces 7:27885–99.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Humeau J, Buqué A, et al. (2020). Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol 17:725–41.
   PubMed Web of Science ®Google Scholar
• Gao R, Zhang Y, Wen XP, et al. (2014). Chemotherapy with cisplatin or carboplatin in combination with etoposide for small-cell esophageal cancer: a systemic analysis of case series. Dis Esophagus 27:764–9.
   PubMed Web of Science ®Google Scholar
• Gomez GG, Hutchison RB, Kruse CA. (2001). Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer. Cancer Treat Rev 27:375–402.
   PubMed Web of Science ®Google Scholar
• Goto K, Ohe Y, Shibata T, et al. (2016). Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 17:1147–57.
   PubMed Web of Science ®Google Scholar
• Gou M, Wei X, Men K, et al. (2011). PCL/PEG copolymeric nanoparticles: potential nanoplatforms for anticancer agent delivery. Curr Drug Targets 12:1131–50.
   PubMed Web of Science ®Google Scholar
• Guo J, Yu Z, Das M, Huang L. (2020). Nano codelivery of oxaliplatin and folinic acid achieves synergistic chemo-immunotherapy with 5-fluorouracil for colorectal cancer and liver metastasis. ACS Nano 14:5075–89.
   PubMed Web of Science ®Google Scholar
• Heigener DF, Manegold C, Jäger E, et al. (2009). Multicenter randomized open-label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose-intensified carboplatin plus etoposide plus lenograstim in small-cell lung cancer in "extensive disease" stage. Am J Clin Oncol 32:61–4.
   PubMed Web of Science ®Google Scholar
• Jiang X, Xin H, Gu J, et al. (2013). Solid tumor penetration by integrin-mediated pegylated poly(trimethylene carbonate) nanoparticles loaded with paclitaxel. Biomaterials 34:1739–46.
   PubMed Web of Science ®Google Scholar
• Jones GS, Elimian K, Baldwin DR, et al. (2020). A systematic review of survival following anti-cancer treatment for small cell lung cancer. Lung Cancer 141:44–55.
   PubMed Web of Science ®Google Scholar
• Kadiyala P, Li D, Nuñez FM, et al. (2019). High-density lipoprotein-mimicking nanodiscs for chemo-immunotherapy against glioblastoma multiforme. ACS Nano 13:1365–84.
   PubMed Web of Science ®Google Scholar
• Karam I, Jiang SY, Khaira M, et al. (2015). Outcomes of small cell lung cancer patients treated with cisplatin–etoposide versus carboplatin–etoposide. Am J Clin Oncol 38:51–4.
   PubMed Web of Science ®Google Scholar
• Kenmotsu H, Niho S, Tsuboi M, et al. (2020). Randomized phase III study of irinotecan plus cisplatin versus etoposide plus cisplatin for completely resected high-grade neuroendocrine carcinoma of the lung: JCOG1205/1206. J Clin Oncol 38:4292–301.
   PubMed Web of Science ®Google Scholar
• Konala VM, Madhira BR, Ashraf S, Graziano S. (2020). Use of immunotherapy in extensive-stage small cell lung cancer. Oncology 98:749–54.
   PubMed Web of Science ®Google Scholar
• Kubota K, Hida T, Ishikura S, et al. (2014). Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study. Lancet Oncol 15:106–13.
   PubMed Web of Science ®Google Scholar
• Li C, Zhang N, Zhou J, et al. (2018). Peptide blocking of PD-1/PD-L1 interaction for cancer immunotherapy. Cancer Immunol Res 6:178–88.
   PubMed Web of Science ®Google Scholar
• Liu J, Shapiro JI. (2003). Endocytosis and signal transduction: basic science update. Biol Res Nurs 5:117–28.
   PubMedGoogle Scholar
• Liu Q, Chen F, Hou L, et al. (2018). Nanocarrier-mediated chemo-immunotherapy arrested cancer progression and induced tumor dormancy in desmoplastic melanoma. ACS Nano 12:7812–25.
   PubMed Web of Science ®Google Scholar
• Melosky B, Cheema PK, Brade A, et al. (2020). Prolonging survival: the role of immune checkpoint inhibitors in the treatment of extensive-stage small cell lung cancer. Oncologist 25:981–92.
   PubMed Web of Science ®Google Scholar
• Minchinton AI, Tannock IF. (2006). Drug penetration in solid tumours. Nat Rev Cancer 6:583–92.
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hunter AC. (2001). Capture of stealth nanoparticles by the body's defences. Crit Rev Ther Drug Carrier Syst 18:527–50.
   PubMed Web of Science ®Google Scholar
• Okamoto H, Watanabe K, Kunikane H, et al. (2007). Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer 97:162–9.
   PubMed Web of Science ®Google Scholar
• Olson ES, Jiang T, Aguilera TA, et al. (2010). Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc Natl Acad Sci U S A 107:4311–6.
   PubMed Web of Science ®Google Scholar
• Ou SH, Ziogas A, Zell JA. (2009). Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity. J Thorac Oncol 4:37–43.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Dvorkin M, Chen Y, et al. (2019). Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394:1929–39.
   PubMed Web of Science ®Google Scholar
• Qiao H, Chen X, Chen E, et al. (2019). Folated pH-degradable nanogels for the simultaneous delivery of docetaxel and an IDO1-inhibitor in enhancing cancer chemo-immunotherapy. Biomater Sci 7:2749–58.
   PubMed Web of Science ®Google Scholar
• Ragavan M, Das M. (2020). Systemic therapy of extensive stage small cell lung cancer in the era of immunotherapy. Curr Treat Opt Oncol 21:64.
   PubMed Web of Science ®Google Scholar
• Rocco D, Della Gravara L, Battiloro C, Gridelli C. (2019). The role of combination chemo-immunotherapy in advanced non-small cell lung cancer. Expert Rev Anticancer Ther 19:561–8.
   PubMed Web of Science ®Google Scholar
• Saleh K, Khalife-Saleh N, Kourie HR. (2019). Finally, after decades, immune checkpoint inhibitors dethroned the standard of care of small-cell lung cancer. Immunotherapy 11:457–60.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, Jemal A. (2021). Cancer Statistics, 2021. CA Cancer J Clin 71:7–33.
   PubMed Web of Science ®Google Scholar
• Tapan U, Furtado VF, Qureshi MM, et al. (2021). Racial and other healthcare disparities in patients with extensive-stage SCLC. JTO Clin Res Rep 2:100109.
   PubMedGoogle Scholar
• Wagner V, Dullaart A, Bock AK, Zweck A. (2006). The emerging nanomedicine landscape. Nat Biotechnol 24:1211–7.
   PubMed Web of Science ®Google Scholar
• Waqar SN, Morgensztern D. (2017). Treatment advances in small cell lung cancer (SCLC). Pharmacol Ther 180:16–23.
   PubMed Web of Science ®Google Scholar
• Yang Z, Ma Y, Zhao H, et al. (2020). Nanotechnology platforms for cancer immunotherapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol 12:e1590.
   PubMed Web of Science ®Google Scholar
• Zhang S, Li S, Cheng Y. (2020). Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: a systematic review and meta-analysis. Thorac Cancer 11:3536–46.
   PubMed Web of Science ®Google Scholar
• Zhou T, Zhang Z, Luo F, et al. (2020). Comparison of first-line treatments for patients with extensive-stage small cell lung cancer: a systematic review and network meta-analysis. JAMA Netw Open 3:e2015748.
   PubMed Web of Science ®Google Scholar